Navigation Links
Echo Therapeutics Announces $3.6 Million Warrant Exercises
Date:1/4/2012

PHILADELPHIA, Jan. 4, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced that it has received warrant exercises generating a total of approximately $3.6 million in cash proceeds.  These warrant exercises bring the company's year-end cash balance to approximately $9.2 million.

"This cash infusion, following the recent positive clinical results for use of our Symphony System, represents important achievements for Echo as we progress toward regulatory clearance and commercialization," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "We believe this additional capital strengthens the balance sheet and will provide greater flexibility in the accelerated product development and clinical validation of our products."

About Echo Therapeutics
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude® SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the safety and efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2010, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio                                                           
Director, Investor Relations and Corporate Communications
(215)717-4104                                                                       

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

 

 

 


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
2. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
3. AuraSense Therapeutics Secures Series B Equity Investment
4. PTC Therapeutics Antibacterial Program Receives $5 Million Award from the Wellcome Trust
5. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
6. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
7. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
8. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
9. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
10. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
11. Echo Therapeutics to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Insightin Health, ... acquisition, retention, and engagement, announced the selection of ... and Product Development, effective as of February 2017. In ... technology implementation strategy for our clients. Wood brings ... in consulting and business analytics within the healthcare ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
(Date:8/2/2017)... Ore. , Aug. 2, 2017  Life Flight Network ... Agreement. The agreement improves patient care and operational efficiency for ... Springfield , Cottage Grove , ... level medical transportation. PeaceHealth and Life Flight Network work collaboratively ... available during transport, or when a time sensitive emergency exists. ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse Executive ... of Trustees for a three-year term beginning January 1, 2018. , The ... are committed to the improvement of health in their communities. Founded in 1898, the ...
(Date:8/20/2017)... ... August 20, 2017 , ... ... ComplyPAK™ Compliance Management System has assisted multiple clients in successfully passing audits ... Service Organization Control Level 2 (AICPA SOC Level 2), and State Data Use ...
(Date:8/19/2017)... California (PRWEB) , ... August 18, 2017 , ... ... a partnership aimed at creating a transparent, verifiable database to help the cannabis ... distributed ledger technology, Paragon hopes to deliver a faster technology with lower fees. ...
(Date:8/19/2017)... San Diego, CA (PRWEB) , ... August 19, 2017 , ... ... Neo-Nazis, and the KKK by saying there are two sides. There are not two ... merely a way to rationalize violence and prejudice, and the NPEIV stands against all ...
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of ... Congo (DRC) thanks to an ambitious venture that conjoined the passions of an NBA ... support of the Liberty community. These shoes will save lives from the rampant infections ...
Breaking Medicine News(10 mins):